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Idiopathic pulmonary fibrosis is a progressive disease and antifibrotic therapies do not reverse existing 
fibrosis. There has been emerging evidence of potential role for statins in idiopathic pulmonary fibrosis. 
The aim of this review is to synthesise the evidence on the efficacy of statins in idiopathic pulmonary 
fibrosis, focusing on associations with all-cause mortality, disease specific mortality and change in 
pulmonary function.  
Methods  
Medline and Embase were reviewed to identify relevant publications. Studies were selected if they 
examined disease related outcomes including mortality, pulmonary function and adverse events in 
people with idiopathic pulmonary fibrosis receiving statin therapy.   
Results   
Five studies with a total of 3407 people with IPF were selected and analysed. The overall risk of bias of 
five included studies was moderate to serious. In the fixed effect meta-analysis, statin use was associated 
with a reduction in mortality (RR 0.8; 95% CI 0.72-0.99). However, in the random effects model, there 
was no longer any significant association between statin use and all-cause mortality (RR 0.87; 95% CI 
0.68-1.12). There was no statistically significant association between statin use and decline in FVC % 
predicted.   
Conclusion:   
There is currently insufficient evidence to conclude the effect of statin therapy on disease-related 
outcomes in idiopathic pulmonary fibrosis. Considering the limitations of available literature, we would 
recommend a prospective cohort study with capture of dosage and preparation of statin, statin 
adherence and use of concurrent antifibrotic treatment.    
PROSPERO registration number: CRD42019122745 
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Idiopathic pulmonary fibrosis (IPF), the most common form of interstitial lung diseases (ILD), is a life-
limiting condition that causes 5000 deaths each year in the UK, and the incidence is increasing in the 
UK1. The pathogenesis of IPF is poorly understood. It is hypothesised that alveolar epithelial cell injury 
triggers release of cytokines such as transforming growth factor beta 1 (TGFß1), platelet-derived growth 
factor (PDGF), and tumour necrosis factor (TNF) α 2,3. Release of these cytokines result in proliferation of 
fibroblast and fibroblast differentiation into the myofibroblast 4, which in turn result in extensive 
extracellular matrix formation and contraction of scar tissue 5,6. Antifibrotic agents, pirfenidone and 
nintedanib, slow decline in pulmonary function, however they do not reverse existing fibrosis.  
Statins are well known for its lipid-lowering properties through inhibition of HMG-CoA reductase. Statins 
also exert immunomodulatory and anti-inflammatory effects via poorly understood mechanisms 7. In 
vitro studies have shown that simvastatin overrides the effect of TGFß1 and inhibits connective tissue 
growth factor (CTGF) gene and protein expressions in IPF-derived fibroblasts 4. Simvastatin also 
decreases alpha smooth muscle actin (α-SMA), a marker of myofibroblast formation, expression via 
inhibition of Rho pathway 4.  
Existing studies have reported divergent findings on the link between statin use and fibrotic disease 
processes. Previously, statin use was considered to be a potential cause of interstitial lung diseases 8,9 
and data from COPDGene study showed association between statin use and interstitial lung 
abnormalities and exacerbated bleomycin induced fibrosis in mice pre-treated with pravastatin 8. 
However, another study showed that pravastatin reduced bleomycin-induced pulmonary fibrosis 10 and a 
similar effect was observed with atorvastatin in mouse model 11. Furthermore, a large cohort study 
conducted in Canada did not show any association between statin use and the incidence of ILD 12. 
However, post hoc analysis of data from the CAPACITY 13 and ASCEND 14 trials indicated that statin use 
was potentially associated with favourable disease-related outcomes in patient with IPF 15. 
Additionally, there has been emerging evidence that statin use may be associated with a favourable 
outcome in terms of fibrosis progression in other conditions. In chronic hepatitis patients, statin therapy 
showed a dose-dependent decreased risk of cirrhosis development 16,17 and lower the risk of 
decompensated liver disease 18,19. However, a recent randomised controlled trial in hypertrophic 
cardiomyopathy did not reveal an association between atorvastatin therapy and left ventricular (LV) 









mass regression or improvement in LV diastolic function 20.  
The potential effect of statin in interstitial fibrosis remains unclear, and to date a systematic review has 
not been conducted. IPF remains a progressive disease and new antifibrotic therapies do not reverse 
existing fibrosis. Therefore, evaluating the effect of the potential adjuvant therapy may offer new 
approaches in the management of IPF. Hence, we aimed to synthesise the evidence on the efficacy of 
statins in IPF, focusing on association between statin use and all-cause mortality, disease-specific 




This systematic review is registered with PROSPERO, registration number: CRD42019122745 
We followed PRISMA reporting standards 21. The initial search was conducted independently by two 
reviewers (JK and KB) between January 2019 and February 2019 and an update search was conducted in 
March 2020.  
Eligibility criteria 
Studies were considered for inclusion if (1) they involved adult participants with diagnosis of IPF (2) 
intervention involving any form of statins irrespective of duration (3) controls including placebo, no statin 
therapy or other IPF therapy (4) reporting disease related outcomes including mortality, pulmonary 
function and adverse events. Eligible study design included observational studies and randomised 
controlled studies. We excluded review papers, comments editorials and non-English language articles. 
We also chose not to consider conference abstracts and grey literature because their data may not have 
undergone full peer review and there would not be sufficient detail for us to conduct our own rigorous 
quality assessment. 
Search strategy  
Medline and Embase were reviewed to identify relevant publications 22. The initial search strategy was 
developed in consideration of previously published systematic reviews 23-25. (Appendix 1) The reference 









lists and citations of relevant studies were screened, and we searched for studies referencing the 
included studies to capture any additional studies. 
Data collection 
The studies were screened by title and abstract by two reviewers (JK and KB) independently using the 
Rayyan online platform (rayyan.qcri.org). Data was extracted by two reviewers (JK and KB) onto data 
collection form using the customised Cochrane data collection form for intervention review for RCTs and 
non-RCTs 26. Any disagreement between reviewers were discussed until resolved.  
Risk of bias 
Risk of bias assessment was independently performed by two reviewers (JK and KB). For non-randomized 
studies, Risk Of Bias In Non-randomized Studies – of Intervention (ROBINS-1) 27 was used. ROBINS-1 tool 
assesses risk of bias due to 1) confounding 2) selection of participants into the study 3) classification of 
interventions 4) intended intervention 5) missing data 6) measurement of outcomes 7) selection of the 
reported results. It classifies risk of bias ‘low’, ‘moderate’, ‘serious’, ‘critical’ and ‘no information’. Overall 
risk of bias is judged to be at low risk of bias if low risk of bias for all domains, at moderate risk of bias if 
low or moderate risk of bias in all domains, at serious risk of bias if at serious risk of bias in at least one 
domain, and at critical risk of bias if at critical risk of bias in at least one domain. A third reviewer was not 
required as there was no disagreement between reviewers.  
Summary measures 
Primary outcome measurements was all-cause mortality, whilst secondary outcomes included disease-
specific mortality and change in pulmonary function in people with IPF. We also explored adverse events, 
change in patient reported outcome measurements and hospital admissions. 
Synthesis of results 
Where more than one study reported the same outcome measured in similar way, a meta-analysis was 
undertaken. Alternatively, a narrative synthesis of the findings was conducted. RevMan software 28 were 
used for statistical analysis. For meta-analysis, we calculated a risk ratio and 95% confidence intervals 
using both fixed effect model and random effect model. Heterogeneity of included studies were 
quantified using the chi-squared test (Q test) and I-squared statistic. I2 was considered might not 









important if 0% to 40%, may represent moderate heterogeneity if 30% to 60%, may represent substantial 
heterogeneity if 50% to 90%, considerable heterogeneity if 75% to 100% 29. 
 
Results 
Study selection and characteristics of the include studies  
The search identified 782 publications with 48 full text articles reviewed. Five studies were selected for 
inclusion. (figure1) Of five, two studies were post hoc analysis of clinical trials, two studies were 
retrospective analyses of patient databases and one study was registry based prospective longitudinal 
study. We did not identify any randomised controlled trials. One study involved adult participants with 
diagnosis of interstitial lung disease and data from IPF patients was included in this review. Table 1 
describes the characteristics of the included studies.  
Risk of bias 
The overall risk of bias of five included studies was moderate to serious. (Table 2) Two studies 15,30 were 
post-hoc analysis of pooled datasets from clinical trials, limiting study population to those who meet 
eligible criteria for clinical trials 13,14,31 and two studies 32,33 were national registry-based studies which 
inherently carry a risk of coding error and missing data 34. One study’s entry criteria 33 limited the study 
population to oxygen dependent patients, who are likely to have advanced disease, registered in 
Swedevox, Swedish registry for long-term oxygen therapy. In this study, data on diagnostic criteria for IPF 
was absent, with estimated 80 per cent of probable IPF. Most studies lack information on duration and 
compliance with statin therapy. Two post-hoc analysis studies used multiple outcome measures with 
possible outcome reporting bias.  
All-cause mortality 
Of five included studies, three studies reported the adjusted all-cause mortality and one study reported 
the adjusted survival. One study reported that statin use was associated with reduced adjusted all-cause 
mortality (HR 0.76; 95% CI 0.62-0.93)35. However, three remaining study did not show association 
between statin therapy and all-cause mortality or survival 15,32,33.  
In the fixed effect meta-analysis, statin use was associated with a reduction in mortality (RR 0.8; 95% CI 









0.72-0.99), but there was moderate heterogeneity between studies (I2=46%). (Figure 2) However, this 
meta-analysis was dominated by the results of one positive study (Vedel-Krogh 2015), and if we used a 
random effects model that distributed the weights more evenly, there was no longer any significant 
association between statin use and all-cause mortality (RR 0.87; 95% CI 0.68-1.12). (Figure 3) 
 
IPF-related mortality  
The adjusted hazard ratio for IPF-related mortality was reported in one post-hoc analysis study which 
suggested that statin use at baseline significantly reduced chance of IPF-related death (HR 0.36; 95% CI 
0.14-0.95, p=0.0393)15.  
 
Decline in pulmonary function 
There was no statistically significant association between statin use and decline in FVC % predicted in 
two post-hoc studies 15,30.  Two studies reported on a composite measure of FVC decline of >10% or 
death. Meta-analysis did not demonstrate any significant relationship between statin use and the 
composite outcome. (Figure 4) 
 
Others 
One study 15 explored the association with hospital admission and showed no statistically significant 
difference in all-cause hospital admission between baseline station uses and non-users. However, the 
difference was statistically significant when adjusted for age, sex, pulmonary function, breathlessness, 
smoking status, and cardiovascular risk factors and medical history (HR 0.58; 95% CI 0.35-0.84, 
p=0.0289). Baseline statin user had statistically significant reduction in respiratory related hospital 
admission than non-users.  
Another post-hoc study reported no statistically difference in time to first acute exacerbation of IPF and 
change in St George’s respiratory questionnaire total score between statin user and non-user at baseline 
30. 











This review did not find a consistent relationship between statin therapy and all-cause mortality or 
decline in pulmonary function in IPF population. A small number of studies were identified, and all 
studies were observational studies or post-hoc analysis studies, inherently carrying issues with missing 
data and selection bias. The meta-analysis was dominated by one large study that reported beneficial 
effects of statins, whereas other smaller studies did not always show similar benefits. We also found 
limited data suggesting that statins may have a possible effect in reducing hospital admissions. 
Furthermore, healthy user bias may have contributed to the findings in observational studies, with 
possible overestimation of the effect of preventative treatment such as statin therapy 33,36. Of five, four 
studies reported the prevalence of cardiovascular disease. The prevalence of cardiovascular disease was 
more common (up to 83%) in statin user compared with non-users (up to 49%).  
One limitation of this review is that we focused our search on published scientific literatures and did not 
screen grey literature as it has not gone through the full peer review. This is because we recognize that 
the full use of the most recent risk of bias tools such as ROBINS-I requires very explicit and 
comprehensive reporting of the primary research study. Additionally, we excluded studies written in 
non-English language, limiting our findings. Among included studies, only two studies reported the 
prevalence of hyperlipidaemia. None of the included studies reported on values of serum cholesterol 
and triglycerides. Only one study reported IPF-related death and the causes of death was missing in the 
majority of studies. 
One study checked for statin prescription at two different time points to ascertain continuous statin use, 
however, there was no information on dosage and adherence. None of the studies collected data on 
adherence to statin therapy. Sub-optimal adherence to statin therapy has been reported in previous 
studies 37,38, and this may have resulted in an under-estimate of statin effects in the studies we included. 
In clinical practice, low-dose statins (e.g. atorvastatin 10mg) are used for primary cardiovascular disease 
prevention and hyperlipidaemia treatment, and high-dose (e.g. atorvastatin 80mg) is prescribed for 
secondary prevention following cardiovascular events. A previous study showed that high dose statin 
therapy resulted in a greater reduction in atherosclerotic plaque inflammation on positron emission 
tomography-computed tomographic imaging (PET-CT), suggesting dose-dependent anti-inflammatory 
effect of statin 39. Different indications for the use of statin therapy and dosage could be potential 









confounding factors.  
Cardiovascular disease is common in people with IPF 40, and occult cardiovascular disease is also 
prevalent 41. Study of COPD and ILD patients, containing 89% IPF patients, undergoing lung transplant 
evaluation with coronary angiography revealed that 63% of ILD patients had angiographically proven 
coronary artery disease but only 20% had established diagnosis of coronary artery disease prior to 
angiography41. This suggests that large proportion of IPF patients have hidden cardiovascular disease 
which could be a potential confounding factor in assessing disease modifying effect of statin in IPF. 
Statin is often used in conjunction with other medications for cardiovascular disease prevention. Kreuter 
et al. (2019) reported on the effect of pairwise combinations of drugs on diseases progression in the 
ASCEND and CAPACITY trials. Multivariable regression based on a multiple pairs of drugs (e.g. statins and 
diabetic medications, statins and anticoagulants) did not yield any consistent evidence of beneficial 
effect when statins were used concomitantly with other drugs42.  
Statin exposure was defined differently in each study. Statin exposure was defined as statin use at 
starting long-term oxygen therapy in one study and at the clinic visit where the diagnosis of IPF was 
made in another study. Only one study used presence of two prescriptions within 6 months before and 
two year before the ILD diagnosis. Other definitions of statin exposure including statin use after the 
diagnosis of ILD was excluded. The remaining two studies, post hoc from clinical trials, defined exposure 
as statin use at baseline. Observational cohort studies in pharmacoepidemiology are vulnerable to bias 
including selection bias and misclassification bias 43. Therefore, future studies should be conducted 
under a robust study design.  
Reviewing the available literature on the effect of statin in people with IPF showed that there is 
insufficient evidence to support a full randomised controlled trial. However, emerging evidence from in 
vitro studies are promising and support antifibrotic effect of statins. In animal study, simultaneous 
treatment with pravastatin and protein kinase C (PKC) inhibitor exerted synergistic antifibrotic effect in 
hepatic fibrosis model through statin-induced activated hepatic stellate cell apoptosis 44. PKC is a family 
of serine-threonine kinase, which is involved in various signalling pathways including TGFß1-mediated 
collagen synthesis in pulmonary fibrosis 45, and inhibition of PKC was associated with attenuated 
ventricular fibrosis following myocardial infarction 46. Pirfenidone showed dose-dependent inhibitory 
effect on PDGF-induced PKC activity in hepatic fibrosis model 47. Additionally, simvastatin inhibited TGF-ß 









mediated Smad-3 signalling pathways which play important roles in fibrogenesis 48. The synergistic effect 
of statins and pirfenidone may be worth further evaluation.   
Conclusion  
There is currently insufficient evidence to conclude the effect of statin therapy on disease-related 
outcomes in idiopathic pulmonary fibrosis. Considering the limitations of available literature, we would 
recommend a prospective cohort study with capture of dosage and preparation of statin, statin 
adherence and use of concurrent antifibrotic treatment.   
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Table 1. Characteristics of the included studies 
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Medline search terms  
1. exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/  
2. HMG-CoA Reductase Inhibitor*  
3. HMG CoA Reductase Inhibitor*  
4. Hydroxymethylglutaryl-CoA Inhibitor*  
5. Hydroxymethylglutaryl-Coenzyme A Inhibitor*  
6. Statin* 
7. (fluvastatin or rosuvastatin or simvastatin or atorvastatin or pravastatin or lovastatin or 
pitavastatin) 
1 or 2 or 3 or 4 or 5 or 6 or 7  
 Combined with   
1. exp Lung Diseases, Interstitial/  
2. (idiopathic interstitial pneumonias or IIP)  
3. fibrosing alveolitis  
4. (usual interstitial pneumonia or UIP)  
5. (Pulmonary Fibrosis or lung fibrosis)  
6. Idiopathic Pulmonary Fibrosis or IPF  
7. interstitial pneumonia/ or usual interstitial pneumonia  
8. Cryptogenic fibrosing alveolitis  
9. (fibrotic NSIP or fibrotic lung disease or fibrotic non-specific interstitial pneumoni* or fibrotic 
non specific interstitial pneumoni*)  
10. ((idiopathic and pulmon* and fibro*) or idiopathic fibrotic)  
11. (cryptogen* and fibros* and alveolit*)  
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
